Navigation Links
Occlutech Wins Confirmation of its Intellectual Property Position Versus AGA Medical Patent by AIPPI
Date:2/7/2008

JENA, Germany, February 7 /PRNewswire/ -- Occlutech GmbH, the leading European manufacturer of coronary occlusion devices today announced that it has obtained approval for its IP position in relation to patents held by AGA Medical Inc. from AIPPI, the European International Association for the Protection of Intellectual Property.

AIPPI is the world's leading non-government organization for research into and protection of intellectual property, and is a respected source for opinions and arbitration on IP matters such as patent interpretation and the use of IP in unfair competition.

In patent infringement litigation filed in Germany by AGA Medical Inc. in 2006, AGA argued and got the courts approval for a broad interpretation of its granted patent claims. During the original grant procedure, however, the Examiners of the European Patent Office did not accept the broad scope of the claims. This created significant reason for Occlutech to appeal the first instance district court's decision that Occlutech literally infringe the AGA patent in Germany and to initiate non-infringement proceedings in several other European countries. Occlutech asked AIPPI for an independent, clarifying opinion which now further supports Occlutech's position.

In a statement Robert Moszner, CEO of Occlutech GmbH said: "We are very pleased with the opinion of AIPPI. In addition to several expert opinions, it strongly supports our view that we are not infringing the patent brought forward by AGA Medical. We have developed a unique technology that is surrounded by its own strong intellectual property and we look forward to having our position confirmed in European and U.S. National courts."

Occlusion devices are used to treat structural heart disease, including structural heart defects and abnormalities such as Atrial Septal Defects, (ASD), and Patent Foramen Ovale (PFO) - an undesired channel between the hearts two atria that is present in up to 25% of the population - in a minimally invasive, non-surgical way. The market for PFO occluders in particular is expected to expand significantly as the link between PFO and strokes, as well as severe migraine, becomes increasingly well-documented.

Occlutech develops and manufactures a wide range of occluders that are sold under the Occlutech Figulla brand in over 40 countries in European and international markets. Clinical programs leading to regulatory approval in the US and Japan are also underway.

Contact:

Robert Moszner

e-mail:robert.moszner@occlutech.com

Phone: +49-3641-67-51-20

Susanne Goransson

e-mail: info@occlutech.info

Phone: +46-704336521


'/>"/>
SOURCE Occlutech GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. John Josef Molenda Joins Firms Intellectual Property Practice as Of Counsel
2. StemCor Systems Announces Acquisition of Intellectual Property to Enhance Bone Marrow Aspiration Platform
3. Written Statement of Kevin J. OConnor, Chairman of the Department of Justice Task Force on Intellectual Property, at the Senate Judiciary Committee Hearing on Intellectual Property Enforcement
4. Therap Services to Attend 2nd International Conference on Intellectual Disabilities/Mental Retardation as Gold Sponsor
5. Depression can foreshadow intellectual decline in older people
6. Mitchell Medical and Jopari Solutions Team up to Offer eBilling Compliance Services to Automobile Property & Casualty Insurance Carriers to Meet New Minnesota Requirements
7. ZIP codes and property values predict obesity rates
8. New Democracy Corps Battleground Poll of Swing Districts Finds Strong, Bi-Partisan Opposition to Cutting Medicare-Funded Nursing Home Care
9. LearnSomething Names Deborah Faucette to New Position of Senior Vice President of Sales and Marketing
10. Herman Miller, Inc., Announces Strategic Acquisition of Brandrud Furniture, Inc. to Expand Its Product Offerings and Competitive Position in the Healthcare Furnishings Sector
11. Start Licensing, Inc. Further Strengthens Position in Cloning Industry With New Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work ... as “patient engagement.” The patient is doing more than filling out a survey; in ... “There is an increasing emphasis in health care and research on the importance of ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor ... prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
(Date:9/19/2017)... ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device ... precise destruction of targeted tissues, announced three leadership team developments today:   ... Stopek, PhD ... ... Veteran medical device executive ...
Breaking Medicine Technology: